Lyra Therapeutics, Inc. — All Filings
369 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
10-Q/A
144
3
4
4/A
424B3
424B4
424B5
8-A12B
8-K
8-K/A
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
POS AM
PRE 14A
REGDEX
REGDEX/A
S-1
S-1/A
S-3
S-8
S-8 POS
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 8-K | 8-K | 0001193125-25-132774 | Jun 2, 2025 | May 27, 2025 |
| 8-K | 8-K | 0001193125-25-122485 | May 19, 2025 | May 14, 2025 |
| 4 | 4 | 0000950170-25-073609 | May 16, 2025 | May 14, 2025 |
| 4 | 4 | 0000950170-25-073611 | May 16, 2025 | May 14, 2025 |
| 4 | 4 | 0000950170-25-073606 | May 16, 2025 | May 14, 2025 |
| 4 | 4 | 0000950170-25-073608 | May 16, 2025 | May 14, 2025 |
| DEFA14A | DEFA14A | 0001193125-25-116890 | May 9, 2025 | — |
| 10-Q | 10-Q | 0000950170-25-064495 | May 6, 2025 | Mar 31, 2025 |
| 8-K | 8-K | 0000950170-25-064475 | May 6, 2025 | — |
| 144 | — | 0001959173-25-002702 | Apr 25, 2025 | — |
| 144 | — | 0001959173-25-002561 | Apr 9, 2025 | — |
| DEF 14A | DEF 14A | 0001193125-25-072918 | Apr 4, 2025 | May 14, 2025 |
| DEFA14A | DEFA14A | 0001193125-25-072923 | Apr 4, 2025 | — |
| PRE 14A | PRE 14A | 0001193125-25-062586 | Mar 25, 2025 | May 14, 2025 |
| 10-K | 10-K | 0000950170-25-038751 | Mar 13, 2025 | Dec 31, 2024 |
| S-8 | S-8 | 0001193125-25-053948 | Mar 13, 2025 | — |
| 8-K | 8-K | 0000950170-25-038742 | Mar 13, 2025 | — |
| SCHEDULE 13G/A | — | 0001104659-25-014360 | Feb 14, 2025 | — |
| 4 | 4 | 0000950170-25-004166 | Jan 10, 2025 | Jan 8, 2024 |
| 4 | 4 | 0000950170-25-004167 | Jan 10, 2025 | Jan 8, 2025 |
| 8-K | 8-K | 0001193125-25-004428 | Jan 10, 2025 | — |
| SC 13D/A | SC 13D/A | 0001193125-24-279927 | Dec 16, 2024 | — |
| 8-K | 8-K | 0001193125-24-278688 | Dec 13, 2024 | Dec 12, 2024 |
| 4 | 4 | 0000950170-24-135515 | Dec 11, 2024 | Dec 9, 2024 |
| 4 | 4 | 0000950170-24-135537 | Dec 11, 2024 | Dec 9, 2024 |
| SC 13G/A | LYRA THERAPEUTICS, INC. | 0000902664-24-006643 | Nov 14, 2024 | — |
| SC 13G/A | LYRA THERAPEUTICS, INC. | 0000902664-24-006556 | Nov 14, 2024 | — |
| SC 13G/A | SC 13G/A | 0001104659-24-119327 | Nov 14, 2024 | — |
| SCHEDULE 13G/A | — | 0001104659-24-119158 | Nov 14, 2024 | — |
| SC 13G/A | SC 13G/A | 0001104659-24-119325 | Nov 14, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-125494 | Nov 12, 2024 | Sep 30, 2024 |
| 8-K | 8-K | 0000950170-24-125455 | Nov 12, 2024 | — |
| 4 | 4 | 0000950170-24-115594 | Oct 18, 2024 | Oct 16, 2024 |
| 4 | 4 | 0000950170-24-115597 | Oct 18, 2024 | Oct 16, 2024 |
| SC 13D/A | SC 13D/A | 0001193125-24-201452 | Aug 15, 2024 | — |
| 8-K | 8-K | 0000950170-24-097007 | Aug 14, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-097042 | Aug 14, 2024 | Jun 30, 2024 |
| 8-K | 8-K | 0001193125-24-182860 | Jul 23, 2024 | Jul 19, 2024 |
| 8-K | 8-K | 0001193125-24-163395 | Jun 18, 2024 | Jun 13, 2024 |
| 4 | 4 | 0000950170-24-073651 | Jun 14, 2024 | Jun 13, 2024 |
| 4 | 4 | 0000950170-24-073646 | Jun 14, 2024 | Jun 13, 2024 |
| 4 | 4 | 0000950170-24-073647 | Jun 14, 2024 | Jun 13, 2024 |
| 4 | 4 | 0000950170-24-073648 | Jun 14, 2024 | Jun 13, 2024 |
| 4 | 4 | 0000950170-24-073649 | Jun 14, 2024 | Jun 13, 2024 |
| 4 | 4 | 0000950170-24-073650 | Jun 14, 2024 | Jun 13, 2024 |
| 8-K/A | 8-K/A | 0001193125-24-157373 | Jun 7, 2024 | May 16, 2024 |
| 8-K | 8-K | 0001193125-24-143419 | May 21, 2024 | May 16, 2024 |
| 8-K | 8-K | 0000950170-24-050525 | Apr 30, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-050535 | Apr 30, 2024 | Mar 31, 2024 |
| DEFA14A | DEFA14A | 0001193125-24-122605 | Apr 29, 2024 | — |